Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma

Published:2021-11-11 Issue:11 Volume:4 Page:e2132262
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Cai Chao¹,Yunusa Ismaeel¹,Tarhini Ahmad²³⁴

Affiliation:

1. Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia

2. Department of Cutaneous Oncology, Moffitt Cancer Center & Research Institute, Tampa, Florida

3. Department of Immunology, Moffitt Cancer Center & Research Institute, Tampa, Florida

4. Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2785982/cai_2021_oi_210920_1635866642.99683.pdf

Reference38 articles.

1. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma.;Yu;Front Immunol,2019

2. Combination of targeted therapy and immunotherapy in melanoma.;Blank;Cancer Immunol Immunother,2011

3. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.;Kakadia;Onco Targets Ther,2018

4. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.;Atkins;Immunotherapy,2019

5. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma.;Khair;Front Immunol,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer;Frontiers in Pharmacology;2024-07-11

2. Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases;Current Treatment Options in Oncology;2023-12

3. Review of pharmacoeconomic studies of melanoma treatment for the period 2018–2023;South Russian Journal of Therapeutic Practice;2023-09-25

4. Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma;The European Journal of Health Economics;2023-07-11

5. A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations;Cancer Medicine;2023-07-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3